ENSC Initiates PF614-MPAR-102 Trial
Ensysce Biosciences initiates final stage of PF614-MPAR-102 clinical trial to evaluate its MPAR overdose-protection technology
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.